Biocon eyes $30b US insulin market via its biosimilars - Business News: Latest News & Videos about market and economy | Trendmergers

Breaking

Post Top Ad

Post Top Ad

Biocon eyes $30b US insulin market via its biosimilars

With the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the US, helping it make a strong entry into that market. This also proves that the company has the science and vertical integration required to get to the US market, it said.

from Industry-Economic Times
Read The Rest:economictimes...

Post Top Ad